# TEZCAT BIOSCIENCES, INC.: A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | TEZCAT BIOSCIENCES, INC. |
| Location | NEW HAVEN, CT |
| Project | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. |
| Project number | 5R44CA265512-03 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $928,698 |
| Awarded | 2026-08-27 |
| Project period | 2022-08-01 to 2027-08-31 |
| UEI | E6EJYYD5BJ23 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11398106). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.